Stiris Research Inc. hits corporate target of First Patient First Visit on Phase 1b Uveal Melanoma study

London, ON — February 2, 2018 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces successfully achieving an Australian biotech’s corporate milestone target of First Patient First Visit (“FPFV”) in their Phase 1b Open label study in Uveal Melanoma metastatic to liver.

Stiris is pleased to announce that the first patient has successfully been entered into the study at the end of January 2018. “The Stiris team are excited that Mt. Sinai in Miami, Florida was the first site to enroll a subject into the study, ahead of the anticipated screening timelines,” said Amanda Carrera, Vice President. “Stiris understands the importance of getting these small patient trials open and enrolled, so that the data can be used by the company for further discussions about moving the product forward.”

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.